Our findings delineate a novel molecular network involving USP49‐mediated autophagy in promoting CBP resistance in RB, offering potential targets for therapeutic intervention to enhance treatment efficacy and improve outcomes for RB patients. Here, USP49 is linked to retinoblastoma.